AbbVie and Frontier Medicines establish global partnership for research and development

▴ AbbVie and Frontier Medicines establish global partnership for research and development
The partnership will address novel therapies and E3 Degraders against difficult-to-drug targets

AbbVie, a research-based global biopharmaceutical company, and Frontier Medicines, Corp., a precision medicine company drugging challenging protein targets to develop breakthrough medicines that change the course of human diseases, announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein targets.

Under the multi-year collaboration, AbbVie and Frontier will utilize Frontier's proprietary chemoproteomics platform to identify small molecules for programs directed to novel E3 ligases and certain oncology and immunology targets.

Whereas conventional drug discovery methodologies have been primarily successful against a relatively discrete set of target classes, chemoproteomics-based screening in relevant cellular contexts has the potential to enable targeting of a significantly broader range of proteins. By selecting certain immunology and oncology targets for the collaboration that are considered well validated but to date, inaccessible, the collaboration has the potential to develop highly differentiated and efficacious therapeutics.

Under the terms of the agreement, AbbVie will pay Frontier an upfront cash payment of $55 million, and Frontier is eligible to receive additional milestone payments. In addition, AbbVie will reimburse Frontier's R&D costs through defined stages of pre-clinical development. The companies will collaborate on the research and pre-clinical development of programs directed against E3 ligase, immunology and oncology targets. Upon successful completion of defined stages of pre-clinical development, AbbVie will assume full responsibility for global development and commercialization activities and costs for the programs. Frontier will retain an option to share development activities and expenses for certain oncology programs through the completion of Phase 2. Frontier will be eligible to receive success-based development and commercial milestone payments that could potentially exceed $1 billion, in addition to royalty payments on commercialized products. AbbVie retains the right to expand the collaboration in the future by exercising options to a defined number of additional targets. The collaboration excludes all of Frontier's internal programs for which Frontier retains exclusive global rights.

"AbbVie is focused on making investments in promising new technologies that assist us in our mission to develop innovative medicines," said Jose-Carlos Gutiérrez-Ramos, Ph.D., vice president, Discovery, AbbVie. "One of our key strategic focus areas is targeted protein degradation and chemoproteomics, and this collaboration with Frontier Medicines will be highly synergistic and complementary to our ongoing efforts."

"AbbVie's commitment to innovative therapies makes them an ideal partner in the development and commercialization of new medicines for cancer and immunological diseases," said Chris Varma, Ph.D., Frontier's co-founder, chairman, and CEO. "With our powerful chemoproteomics platform, we are greatly expanding the universe of therapeutic targets that can be accessed with small molecule drugs. This partnership enables us to build a shared pipeline of novel therapeutics with AbbVie, while Frontier continues to independently advance our internal programs into the clinic."

Tags : #Abbvie #FrontierMedicines #AbbvieGlobalPartnershipFrontierMedicine #LatestPharmaNewsDec4 #LatestPharmaCollabarationDec4 #NovelTherapies

About the Author


Team Medicircle

Related Stories

28 Mar

Type 2 Diabetes Under Attack: The Unexpected Power of Wearable Tech

As research continues to explore the benefits of digital health interventions, it is clear that the future of diabetes care lies at the intersection of technology and lifestyle.

View
22 Mar

39th Prof. M. Viswanathan Oration Highlights Strategies to Prevent Diabetic Foot Amputations

Dr. Viswanathan stressed the urgent need for a holistic and integrated approach to diabetes management. He called for coordinated interventions across the healthcare sector, involving the government, medical professionals, and the community, to curb India’s diabetes epidemic and prevent further strain on healthcare resources.

View
21 Mar

Can Giving Blood Lower Your Risk of Heart Disease and Diabetes? Find Out

The biggest motivation for donating blood remains helping someone in desperate need while possibly improving your own health in the process.

View
23 Jan

When a Government Hospital Became a Lifesaver: The Story of India’s First ‘Mechanical Heart’ Implant

The Army Hospital’s achievement is a shining example of how determination and skill can overcome even the most daunting challenges.

View
16 Jan

Could Engineered Cells Be the Cure-All Medicine We’ve Been Waiting For?

This innovation holds the promise of a future where medicine is not just reactive but proactive, where treatments are not only effective but also tailored to individual needs.

View
20 Dec

Biobank Blueprint: Redefining Diabetes Diagnosis and Treatment in India

With the insights and innovations it is expected to generate, this biobank could well be the key to turning the tide against India’s diabetes epidemic.

View
14 Dec

A New Dawn for Eye Health in Obesity: How Bariatric Surgery Repairs Early Eye Damage

It’s a breakthrough that brings hope, highlights the importance of early intervention, and showcases the need for a holistic approach to health.

View
27 Nov

Fat’s Double-Edged Sword: How It Protects and Betrays Your Health

The answer to diabetes may lie not in shrinking fat but in making it work better. This discovery offers a transformative vision for a healthier future

View
11 Nov

Are You at Risk? AI Data Exposes Unseen Triggers of Diabetes in Our Environment

By embracing AI technology, a diverse dataset, and a collaborative spirit, the researchers have set the stage for a new era in diabetes care.

View
23 Oct

Young, Reckless, and Stroke-Prone: Is Alcohol Quietly Killing Our Generation?

Other than alcohol, obesity, type 2 diabetes, high stress levels, lack of sleep, and unhealthy diets are also closely linked to increased stroke risk.

View

-Advertisements-




Trending Now

The Digital Sleep Thief: How Night-time Screen Addiction is Robbing You of Bed-time RestApril 02, 2025
KKR Launches ‘Knight Bite’ – A Digital Series That Serves Up Food, Fun, and Cricket!April 02, 2025
Crompton rolls out its all new range of Aura, Avancer & Jedi Air Coolers for an effortless summer cooling experienceApril 02, 2025
CARE Hospitals, Hi-Tech City Strengthens Orthopaedics Department with Renowned SurgeonsApril 02, 2025
World Autism Awareness Day: Breaking the Chains of Stigma in IndiaApril 02, 2025
From Scroll to Squint: How Reels Are Reshaping Your VisionApril 02, 2025
Moscow Center for Diagnostics and Telemedicine Receives License for Radiology Residency ProgramApril 02, 2025
CARE Hospitals Launches AI-Powered Non-Invasive Therapy – An innovative modality introduced in Telangana & Andhra PradeshApril 02, 2025
High-Rise Heart Attacks: Are Skyscrapers Turning Survival into a Race Against Time?April 02, 2025
DCDC’s $150 Crore Expansion: Can Innovative Clinics End India's Kidney Crisis?April 02, 2025
Medanta Rolls Out ‘Colon Tunnel on Wheels’ to Drive Awareness on Colorectal Cancer Prevention & Early DetectionApril 01, 2025
Zigly launches 2 pet hospitals, opens 4 new stores; expects ARR to more than double in 1-2 yearsApril 01, 2025
University of Leeds Announces International Masters Regional Scholarships for 2025April 01, 2025
Avantor Recognized with Two Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2025April 01, 2025
Foundation Stone Laid for Madhav Netralaya Eye Hospital & Research CentreApril 01, 2025
Doomscrolling at Midnight: How Indians Are Sacrificing Sleep for ScreensMarch 31, 2025
Essential Medicines Price Surge: Are Patients Paying the Price?March 31, 2025
Prioritize your health during the holy days of RamzanMarch 31, 2025
Tired of Stomach Cramps? These Simple Foods Can Heal Your GutMarch 31, 2025
Regional growth booming for startups in 2024 - QBO Innovation studyMarch 31, 2025